Health & Biotech
Weed Week: Cannabis boom a ‘matter of when, not if’; and NSW to allow residents to grow pot
Health & Biotech
ASX Health Stocks: Imugene wins ‘intention to grant’ cancer vaccine patent, Phase 2 trial in 2024
Health & Biotech
PharmAust bolsters leadership as CEO attends global ALS/MND Symposium
Health & Biotech
ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome
Health & Biotech
Neurotech to extend Phase 2/3 autism spectrum disorder trial to adults
Health & Biotech
ASX Health Stocks: Compumedics granted FDA clearance; Botanix receives FDA feedback
Health & Biotech
ASX Health Winners: Biotechs up 10pc in November, and Janus Henderson’s prediction for 2024
Health & Biotech
PharmAust completes Phase 1 motor neurone disease trial, applies for Orphan Drug Designation
Health & Biotech
ASX Health Stocks: Clarity Pharma says its drug could be effective in prostate cancer, shares jump 8pc
Health & Biotech
‘Best place we’ve ever been’: AdAlta looks to monetise lead asset in 2024
Health & Biotech
On the rise: Erectile dysfunction nasal spray inventor LTR Pharma firms for ASX and major market disruption
Health & Biotech
Check Up: Imugene’s oncolytic virus VAXINIA granted FDA’s Fast Track, but how effective is this novel therapy?
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.